Skip to main content
SpringerLink
Log in
Book cover

Retroviral Immunology pp 317–329Cite as

Immunologic Approaches to the Therapy of Patients with HIV Infection

  • Chapter

  • 150 Accesses

Part of the book series: Infectious Disease ((ID))

Abstract

The primary modality of therapy for patients with human immunodeficiency virus (HIV) infection is the use of combination antiretroviral chemotherapy to suppress HIV replication. As has been clearly established by a number of studies, effective suppression of HIV replication leads to an immediate improvement in immune function as evidenced by a marked decrease in opportunistic infections and increases in the naïve and memory CD4 T cell pools (1–4). Unfortunately, it has also been clearly established that as a single approach, antiretroviral therapy only suppresses but does not eradicate HIV infection and thus life-long therapy is likely to be required in many patients (5). Given the concerns about long-term toxicities and the development of resistance there remains an interest in looking at alternatives to antiretroviral therapy alone. Immunologic approaches to therapy involve interventions that directly modulate the immune system.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients in fected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725–30.

    Article  PubMed  CAS  Google Scholar 

  2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 1998; 338: 853–60.

    Article  PubMed  Google Scholar 

  3. Kelleher AD, Can A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321–9.

    Article  PubMed  CAS  Google Scholar 

  4. Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997; 3: 533–40.

    Article  PubMed  CAS  Google Scholar 

  5. Sereti I, Gea-Banacloche JC, Kan M-Y, Hallahan CW, and Lane HC. Interleukin-2 leads to dose dependent expression of the alpha chain of the IL-2 receptor on CD25 negative T lymphocytes in the absence of antigenic stimulation. Clin Immuno12000; 97: 266–76.

    Google Scholar 

  6. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999; 13: F59–62.

    Article  PubMed  CAS  Google Scholar 

  7. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT Jr, Falloon J, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995; 332: 567–75.

    Article  PubMed  CAS  Google Scholar 

  8. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350–6.

    Article  PubMed  CAS  Google Scholar 

  9. Carr A, Emery S, Lloyd A, Hoy J, Garsia R, French M, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethyleneglycol-modified interleukin-2 in human immunodeficiency virus-infected patients: arandomized, controlled, multicenter study. Australian IL-2 Study Group. J Infect Dis 1998; 178: 992–9.

    Article  PubMed  CAS  Google Scholar 

  10. Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 1999; 353: 1923–9.

    Article  PubMed  CAS  Google Scholar 

  11. Levy Y, Capitant C, Houhou S, Carriere I, Viard JP, Goujard C, Gastaut JA, Oksenhendler E, Boum-sell L, Gomard E, Rabian C, Weiss L, Guillet JG, Delfraissy JF, Aboulker JP, Seligmann M. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomized controlled, trial. ANRS 048 study group. Lancet. 1999 Jun 5; 353 (9168): 1923–9.

    Article  CAS  Google Scholar 

  12. Losso MH, Belloso, WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, Lopardo G, Salomon H, et al. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous Interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus infected patients with CD4+ cell counts_ 350/mm3. J Inf Dis 2000; 181: 1614–21.

    Article  CAS  Google Scholar 

  13. Ruxrungtham K, Suwanagool S, Tavel JA, Chuenyam M, Kroon E, Ubolyam S, Buranapraditkun S, Techasathit W, Li Y, Emery S, Davey DR, Fosdick L, Kunanusont C, Lane HC, Phanuphak P, and the Vanguard Study Group. A randomized, controlled 24 week study of intermittent subcutaneous interleukin-2 (scIL-2) in HIV-1 infected patients in Thailand. AIDS 14: 2509–13.

    Google Scholar 

  14. Hengge UR, Goos M, Esser S, Exner V, Dotterer H, Wiehler H, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS 1998; 12: F225–34.

    Article  PubMed  CAS  Google Scholar 

  15. Am A, Ruiz L, Juan M, Jou A, Balagu M, Zayat MK, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with M=250/µL CD4 T cells and undetectable plasma virus load. J Infect Dis 1999; 180: 56–60.

    Article  Google Scholar 

  16. Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179: 849–58.

    Article  PubMed  CAS  Google Scholar 

  17. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5: 651–5.

    Article  PubMed  CAS  Google Scholar 

  18. Davey RT, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999 Dec 21; 96 (26): 15109–14.

    Article  CAS  Google Scholar 

  19. Emery S, Capra WB, Cooper DA, Mitsuyasu RT, Kovacs JA, Vig P, Smolskis M, Saravolatz LD, Lane HC, Fyfe GA, and Curtin PT for the International IL-2 Study Group. Pooled-analysis of three, randomised, controlled trials of interleukin-2 therapy in adult HIV disease. J Inf Dis 2000; 182: 428–34.

    Article  CAS  Google Scholar 

  20. Keiser P, Rademacher S, Smith JW, Skiest D, Vadde V. Granulocyte colony stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 1998; 104: 48–55.

    Article  PubMed  CAS  Google Scholar 

  21. Kuritzkes DR, Parenti D, Ward Dj, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 1998; 12: 65–78.

    Article  PubMed  CAS  Google Scholar 

  22. Nielsen SD, Afzelius P, Dam-Larsen S, et al. Effect of G-CSF in HIV-infected patients: increase in numbers of naïve CD4+ cells and CD34+ cells. AIDS 1998; 12:Suppl 4, S64.

    Google Scholar 

  23. Tulpule A, Joshi B, DeGuzman N, Espina BM, Mocharnuk R, Prakash O, et al. Interleukin-4 in the treatment of AIDS-related Kaposi’s sarcoma. Ann Oncol 1997; 8: 79–83.

    Article  PubMed  CAS  Google Scholar 

  24. Lane HC, Masur H, Long DL, Klein HG, Rook AH, Quinnan GV, et al. Partial immune reconstruction in a patient with the acquired immunodeficiency syndrome. N Engl J Med 1984; 311: 1099–103.

    Article  PubMed  CAS  Google Scholar 

  25. Levine BL, Cotte J, Small CC, Carroll RG, Riley JL, Bernstein WB, et al. Large-scale production of CD4+ T cells from HIV-1 infected donors aftner CD3/CD28 costimulation. J Hematother 1998; 7: 437–48.

    Article  PubMed  CAS  Google Scholar 

  26. Trickett AE, Kelly M, Cameron BA, Lloyd A, French RA, Dwyer JM. A preliminary study to determine the effect of an infusion of cryopreserved autologous lymphocytes on immunocompetence and viral load in HIV-infected patients. J Acquir Immune Defic Hum Retrovirol 1998; 17: 129–36.

    Article  CAS  Google Scholar 

  27. Woffendin C, Ranga U, Yang Z, Xu L, Nabel GJ. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 1996; 93: 2889–94.

    Article  PubMed  CAS  Google Scholar 

  28. Morgan RA, Walker R. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum Gene 1996; 7: 1281–306.

    CAS  Google Scholar 

  29. Poli G, Kinter AL, Vicenzi E, Fauci AS. Cytokine regulation of acute and chronic HIV infection in vitro: from cell lines to primary mononuclear cells. Res Immunol 1994; 145: 578–82.

    Article  PubMed  CAS  Google Scholar 

  30. Andrieu JM, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immuodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995; 171: 523–30.

    Article  PubMed  CAS  Google Scholar 

  31. Kilby JM, Tabereaux PB, Mulanovich V, Shaw GM, Bucy RP, Saag MS. Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss. AIDS Res Hum Retrovir 1997; 13: 1533–7.

    Article  PubMed  CAS  Google Scholar 

  32. Walker RE, Spooner KM, Kelley G, McCloskey RV, Woody JN, Falloon J, et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 1996; 174: 63–8.

    Article  PubMed  CAS  Google Scholar 

  33. Makonkawkeyoon S, Limson-Pobre RN, Moreira AL, Schaur V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 5974–8.

    Article  PubMed  CAS  Google Scholar 

  34. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Eng J Med 1997; 336: 1487–93.

    Article  CAS  Google Scholar 

  35. Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type I and M. tuberculosis infection. J AIDS Hum Retrovirol 1996; 11: 247–57.

    CAS  Google Scholar 

  36. Haslett P, Tramontana J, Burroughs M, Hempstead M, Kaplan G. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 24: 1223–7.

    Article  PubMed  CAS  Google Scholar 

  37. deWaal-Malefyt R, Abrams J, Bennett B, Fidgor C, deVries J. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209–20.

    Article  CAS  Google Scholar 

  38. Chen WF, Zlotnik A. IL-10: a novel cytotoxic T cell differentiation factor. J Immunol 1991; 147: 528–34.

    PubMed  CAS  Google Scholar 

  39. Weissman D, Poli G, Fauci AS. Interleukin-10 blocks HIV replication in macrophages by inhibiting the autocrine loop of TNF-a and IL-6 induction of virus. AIDS Res Hum Retrovir 1994; 10: 1199–206.

    Article  PubMed  CAS  Google Scholar 

  40. Muller F, Aukrust P, Nordoy I, Froland SS. Possible role of interleukin-10 and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Blood 1998; 92: 3721–29.

    PubMed  CAS  Google Scholar 

  41. Birx DL, Davis C, Ruiz N, et al. Results of phase II double-blinded, multicenter, placebo controlled HIV therapeutic vaccine trial. In: XI International Conference on AIDS, Vancouver, July, 1996 (Abstr TuA275).

    Google Scholar 

  42. Tsoukas CM, Raboud J, Bernard NF, Montaner JS, Gill MJ, Rachlis A, et al. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency. AIDS Res Hum Retrovir 1998; 14: 483–90.

    Article  PubMed  CAS  Google Scholar 

  43. Sandstrom E, Wahren B, the Nordic VAC-04 Study Group. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: a randomised double-blind placebo-controlled trial. Lancet 1999; 353: 1735–42.

    Article  PubMed  CAS  Google Scholar 

  44. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278: 1447–50.

    Article  PubMed  CAS  Google Scholar 

  45. Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S. Evaluation of HIV-1 immunogen, an immunologic modiffier, administered to patients infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A randomized controlled trial. JAMA 2000; 284 (17): 2193–202.

    CAS  Google Scholar 

  46. Ugen KE, Nyland SB, Boyer JD, Vidal C, Lera L, Rasheid S, et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998; 16: 1818–21.

    Article  PubMed  CAS  Google Scholar 

  47. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998; 178:92–100. Lancet 1998; May 2; 351: 1320–5.

    Google Scholar 

  48. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998; 351: 1320–5.

    Article  PubMed  CAS  Google Scholar 

  49. Tubiana R, Gomard E, Fleury H, Gougeon ML, Mouthon B, Picolet H, Katlama C. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS 1997; 11: 819–20.

    PubMed  CAS  Google Scholar 

  50. Levy J, Youvan T, Lee ML. Passive hyperimmune plasma therapy in the treatment of acquired immunodeficiency syndrome: results of a 12-month multicenter double-blind controlled trial. The Passive Hyperimmune Therapy Study Group. Blood 1994; 84: 2130–5.

    PubMed  CAS  Google Scholar 

  51. Vittecoq D, Chevret S, Morand-Joubert L, Heshmati F, Audat F, Bary M, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs.transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995; 92: 1195–9.

    Article  PubMed  CAS  Google Scholar 

  52. Gauduin MC, Parren PWHI, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997; 3: 1389–93.

    Article  PubMed  CAS  Google Scholar 

  53. Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10: 431–8.

    Article  PubMed  CAS  Google Scholar 

  54. Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisnewski A, et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retrovir 1998; 14: 545–50.

    Article  PubMed  CAS  Google Scholar 

  55. Gunthard HF, Gowland PL, Schupbach J, Fung MS, Boni J, Liou RS, et al. A phase I/IIA clinical study with a chimeric mouse-human monoclonal antibody to the V3 loop of human immunodeficiency virus type 1 gp120. J Infect Dis 1994; 170: 1384–93.

    Article  PubMed  CAS  Google Scholar 

  56. Bex F, Hermans P, Sprecher S, Achour A, Badjou R, Desgranges C, et al. Syngeneic adoptive transfer of anti-human immunodeficiency virus (HIV-1)-primedlymphocytes from a vaccinated HIV-seronegative individual to his HIV-1-infected identical twin. Blood 1994; 84: 3317–26.

    PubMed  CAS  Google Scholar 

  57. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 200 Jul 15; 96(2):467–74.

    Google Scholar 

  58. Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, Bakker A, Roberts MR, June CH, Jalali S, Lin AA, Pennathur-Das R, Hege KM. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000 Aug 1; 96 (3): 785–93.

    CAS  Google Scholar 

  59. Koenig S, Conley AJ, Brewah YA, Jones GM, Leath S, Boots LJ, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995; 1: 330–6.

    Article  PubMed  CAS  Google Scholar 

  60. Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216–23.

    Article  PubMed  CAS  Google Scholar 

  61. Brodie SJ, Lewinsohn DA, Patterson BK, Jiyamapa D, Krieger J, Corey L, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med 1999; 5: 34–41.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. H. Clifford Lane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Seeley
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hospital de Beaumont, Lausanne, Switzerland

    Giuseppe Pantaleo MD

  2. Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Bruce D. Walker MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Lane, H.C., Seeley, S. (2001). Immunologic Approaches to the Therapy of Patients with HIV Infection. In: Pantaleo, G., Walker, B.D. (eds) Retroviral Immunology. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-110-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-110-7_14

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-128-8

  • Online ISBN: 978-1-59259-110-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation